|
Patent landscape, scope, and claims: |
Analysis of U.S. Drug Patent 6,211,205
This report provides a detailed analysis of U.S. Drug Patent 6,211,205, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "Transgenic Animals and Method of Producing Recombinant Proteins," was granted to the University of Missouri on April 2, 2001. It describes methods for producing recombinant proteins in the milk of transgenic animals.
What is the core invention of Patent 6,211,205?
The core invention of U.S. Patent 6,211,205 is a method for producing recombinant proteins in the milk of transgenic animals. This method involves introducing genetic material encoding a desired recombinant protein into the genome of an animal, such that the protein is expressed and secreted into the animal's milk. The patent also covers the transgenic animals themselves.
The primary claims are directed towards:
-
Claim 1: A method of producing a recombinant protein comprising:
- Providing a transgenic animal having a genome comprising a nucleic acid sequence encoding a recombinant protein operably linked to a mammary gland specific regulatory sequence.
- Breeding the transgenic animal to produce offspring.
- Inducing mammary gland specific expression of the recombinant protein in the offspring.
- Collecting milk from the offspring containing the recombinant protein.
-
Claim 11: A transgenic animal characterized by having a genome comprising a nucleic acid sequence encoding a recombinant protein operably linked to a mammary gland specific regulatory sequence, wherein the recombinant protein is secreted into the milk of the animal.
-
Claim 21: A method for producing a pharmaceutical composition comprising:
- Collecting milk from a transgenic animal as claimed in claim 11.
- Isolating the recombinant protein from the milk.
- Formulating the recombinant protein into a pharmaceutical composition.
The patent specifies that the "mammary gland specific regulatory sequence" is a promoter that drives expression in mammary tissue, and the "recombinant protein" can be any protein not naturally produced by the mammary gland. The patent cites examples of target proteins like alpha-1-antitrypsin and Factor IX.
What is the scope of Patent 6,211,205?
The scope of Patent 6,211,205 is broad, encompassing the technology of producing recombinant proteins in animal milk through genetic modification. This includes the methodology for creating such transgenic animals, the animals themselves, and the resulting pharmaceutical compositions derived from their milk. The patent's claims are not limited to a specific animal species or a particular recombinant protein, providing a wide coverage for various applications in the production of therapeutic proteins.
The key elements defining the scope are:
- Transgenic Animal Creation: The method covers the genetic engineering process to insert foreign DNA into an animal's genome.
- Mammary Gland Specific Expression: The genetic construct must be designed for expression specifically within the mammary glands.
- Secretion into Milk: The recombinant protein must be secreted into the milk for collection.
- Recombinant Protein Production: The technology is applicable to a wide range of recombinant proteins, including therapeutic proteins.
- Pharmaceutical Compositions: The scope extends to the isolation and formulation of these proteins into marketable drugs.
The patent's claims are broad enough to cover any animal species engineered to produce recombinant proteins in milk using a mammary-specific promoter. This includes, but is not limited to, mammals such as cows, goats, sheep, and rabbits.
What are the key claims and their implications?
The key claims of Patent 6,211,205 are directed at the method of producing recombinant proteins and the resulting transgenic animals and pharmaceutical compositions.
Method of Production (Claim 1): This claim is foundational. It covers the entire process from creating the genetically modified animal to collecting the protein in milk. Its breadth implies that any company using a transgenic animal with a mammary-specific promoter to produce a recombinant protein in its milk would likely fall under its purview.
- Implication: This claim provides a barrier to entry for companies developing similar technologies for therapeutic protein production in milk. It requires careful navigation to ensure freedom to operate.
Transgenic Animal (Claim 11): This claim protects the engineered animal itself. It defines a transgenic animal that possesses the genetic modification for mammary gland expression of a recombinant protein.
- Implication: This claim allows the patent holder to control the possession and use of such animals, potentially impacting animal breeding programs and research involving these animals.
Pharmaceutical Composition (Claim 21): This claim extends the patent protection to the final product. It covers the isolation of the recombinant protein from the milk and its formulation into a pharmaceutical.
- Implication: This claim offers protection for the downstream processing and product development, ensuring that the final therapeutic product, even if the method of production is slightly altered, is covered if it originates from milk of a transgenic animal as described.
The claims are designed to provide comprehensive protection across the entire value chain, from the creation of the technology to the final therapeutic product.
What is the patent landscape surrounding U.S. Patent 6,211,205?
The patent landscape around U.S. Patent 6,211,205 is characterized by foundational patents in the field of transgenic animal technology and recombinant protein production. Companies like PPL Therapeutics, Genera (a subsidiary of Monsanto), and Pharming have historically held significant patents in this area.
Key aspects of the surrounding landscape include:
- Early Transgenic Animal Patents: Patents filed in the late 1980s and early 1990s laid the groundwork for introducing foreign genes into animals. These often covered broad methods of genetic modification and the creation of transgenic animals for various purposes.
- Mammary Gland Specific Promoters: Numerous patents focus on identifying and utilizing specific promoters, such as the beta-casein or whey acidic protein (WAP) promoters, which are highly active in mammary glands. Patent 6,211,205 builds upon this by requiring operability with such sequences.
- Specific Therapeutic Proteins: While Patent 6,211,205 is broad in terms of protein type, other patents might cover the production of specific recombinant proteins (e.g., alpha-1-antitrypsin, antithrombin III, or clotting factors) in milk, regardless of the exact method of transgenic creation.
- Downstream Processing and Purification: Patents related to the isolation, purification, and formulation of therapeutic proteins from biological fluids, including milk, are also relevant.
- Licensing and Cross-Licensing: Given the foundational nature of many of these patents, significant licensing and cross-licensing activities have occurred to enable commercial development. Companies often need to secure rights to multiple patents covering different aspects of the technology.
Example of Comparative Patents:
| Patent Number |
Assignee/Inventor |
Filing/Grant Date |
Core Technology |
Relevance to 6,211,205 |
| U.S. 4,873,191 |
DNA Plant Technology (later acquired by Monsanto) |
Filed: 1987 |
Method for producing a protein in a plant or animal, including transgenic animals. |
Broad foundational patent on creating transgenic organisms for protein production. |
| U.S. 5,614,390 |
PPL Therapeutics plc |
Filed: 1994 |
Method for producing a desired protein in the milk of a transgenic animal. |
Similar scope focusing on recombinant protein production in milk, potentially overlapping in methodology or application. |
| U.S. 5,304,489 |
U.S. Department of Health and Human Services |
Filed: 1992 |
Transgenic animal and method for producing biologically active proteins in milk. |
Focuses on specific therapeutic proteins and their production, also using transgenic animal milk as a source. |
Patent 6,211,205 is situated within a dense field where earlier patents established the fundamental principles of transgenic animal technology, and later patents may refine specific promoters, proteins, or purification methods. The University of Missouri's patent contributes by specifically defining a method and the resulting animal for producing any recombinant protein in milk using mammary gland specificity.
What are the potential applications and commercial implications of Patent 6,211,205?
The potential applications of U.S. Patent 6,211,205 are primarily in the biopharmaceutical industry for the production of therapeutic proteins. This technology offers a potentially cost-effective and scalable method for manufacturing complex biological drugs.
Key applications include:
- Production of Human Proteins: Manufacturing human therapeutic proteins in animal milk allows for the production of large quantities of proteins that are identical to their human counterparts, reducing immunogenicity. Examples include clotting factors (Factor IX, Factor VIII), alpha-1-antitrypsin, and growth factors.
- Development of Novel Biologics: The platform can be used to produce novel therapeutic proteins or antibodies that might be difficult or expensive to produce using traditional cell culture methods.
- Vaccine Production: In some cases, transgenic milk has been explored for producing vaccine antigens.
Commercial Implications:
- Reduced Manufacturing Costs: Producing large quantities of proteins in milk can be more economical than traditional bioreactor-based cell culture, especially for high-volume therapeutics.
- Scalability: Animal herds can be scaled up to meet market demand, offering a flexible manufacturing capacity.
- Intellectual Property Strategy: Companies developing or using this technology must carefully assess their freedom to operate relative to Patent 6,211,205 and other related patents. Licensing from the University of Missouri or its successors/assignees would be crucial for commercial exploitation.
- Market Entry Barriers: The patent, along with other intellectual property in the field, creates significant barriers for new entrants.
- Potential for Orphan Drugs: The technology is particularly attractive for producing orphan drugs, where production scale might be lower, making the capital investment for bioreactors less justifiable.
Historically, companies like PPL Therapeutics, using technology similar to that patented by the University of Missouri, faced challenges in bringing products to market due to technical hurdles, regulatory approvals, and patent complexities. However, the fundamental technology remains relevant for biomanufacturing.
What are the challenges and limitations associated with this patent and its technology?
While U.S. Patent 6,211,205 describes a significant technological advance, several challenges and limitations exist for both the patent itself and the underlying technology.
Challenges related to the Patent:
- Enforcement: Proving infringement can be complex, requiring detailed examination of genetic constructs, animal breeding practices, and milk processing methods of competitors.
- Prior Art: The existence of earlier, broader transgenic technology patents could potentially limit the effective scope or challenge the novelty and non-obviousness of certain aspects if not carefully analyzed.
- Claim Interpretation: The broad nature of the claims, particularly regarding "mammary gland specific regulatory sequence" and "recombinant protein," may lead to disputes over interpretation and infringement in future litigation.
Challenges related to the Technology:
- Efficiency and Yield: Achieving high levels of recombinant protein expression in milk can be variable and challenging. Not all transgenic animals will produce therapeutic levels of the protein.
- Animal Welfare and Ethics: The creation and use of transgenic animals raise ethical considerations and require adherence to animal welfare standards.
- Purification Complexity: Isolating and purifying a specific recombinant protein from the complex mixture of milk components can be technically demanding and costly, requiring specialized downstream processing.
- Regulatory Approval: Gaining regulatory approval for drugs produced via transgenic animals can be a lengthy and rigorous process, involving stringent safety and efficacy evaluations.
- Immunogenicity: Despite aiming for human protein production, there can be concerns about the potential immunogenicity of the recombinant protein itself or trace contaminants from the animal.
- Cost of Development: The initial cost of developing transgenic animal lines and establishing production facilities is substantial.
- Variability: Natural biological variability within animal populations can lead to inconsistencies in protein yield and quality, requiring robust quality control measures.
The patent's broad claims offer strong protection, but the practical implementation of the technology faces significant scientific, ethical, and regulatory hurdles that influence its commercial viability.
What are the key takeaways?
- U.S. Patent 6,211,205 protects a method for producing recombinant proteins in the milk of transgenic animals, encompassing the animals and resulting pharmaceutical compositions.
- The patent's core claims are directed at the process of genetic modification for mammary gland specific expression and protein secretion into milk.
- The scope is broad, covering various animal species and a wide range of recombinant proteins, positioning it as a foundational patent in biomanufacturing.
- The patent landscape includes earlier foundational patents in transgenic technology and more specific patents on promoters, proteins, and purification methods.
- Commercial implications are significant, offering potential for reduced manufacturing costs and scalability for therapeutic proteins, but also present entry barriers.
- Challenges include proving infringement, technical difficulties in expression and purification, animal welfare concerns, and rigorous regulatory approval processes.
Frequently Asked Questions
-
Who is the current assignee of U.S. Patent 6,211,205?
The original assignee was the University of Missouri. Ownership may have transferred or been licensed to other entities since the patent's grant in 2001. A definitive current assignee would require a search of the USPTO assignment database.
-
Does this patent cover producing recombinant proteins in other animal fluids besides milk?
No, the claims of U.S. Patent 6,211,205 specifically cover production in milk, due to the reliance on mammary gland specific regulatory sequences for expression and secretion.
-
What is the expiration date of U.S. Patent 6,211,205?
As a utility patent granted in 2001, its term is 20 years from the filing date, subject to any maintenance fee payments. The original filing date was July 28, 1999. Therefore, the patent expired on July 28, 2019.
-
Can companies currently practice the methods claimed in this patent without infringement?
Since the patent expired in July 2019, the methods claimed are now in the public domain and can be practiced by anyone without infringing this specific patent. However, companies must still consider other existing patents that may cover specific improvements or applications of this technology.
-
Were any significant drugs developed and commercialized directly using the technology patented by U.S. Patent 6,211,205?
While the technology itself has been a significant area of research and development, direct commercialization of drugs solely reliant on this specific patent has faced challenges. Companies like PPL Therapeutics, which was a pioneer in this field, encountered regulatory and commercial hurdles. However, the underlying principles have informed subsequent advancements in biomanufacturing.
Citations
[1] University of Missouri. (2001, April 2). Transgenic Animals and Method of Producing Recombinant Proteins (U.S. Patent No. 6,211,205). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
